All In MedTech

FDA Clearance Tracker · P170027-S001

TherOx DownStream System

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Nov 20, 2020 (this decision)Source: openFDAMethods & limitations

PMA supplement

The decision

FDA number
P170027-S001
Device name
TherOx DownStream System
Applicant location
San Jose, CA
Received
Apr 29, 2019
Decided
Nov 20, 2020
Decision
Approved
Supplement type
Normal 180 Day Track No User Fee
Reason for supplement
Postapproval Study Protocol
Original approval
P170027

Device type

Device class
Class III
Specialty
Cardiology

Every decision under product code MWG

FDA's approval statement

As written in FDA's record.

Approval for the Therox Downstream System. The device is indicated for the preparation and delivery of SuperSaturated Oxygen Therapy (SSO2 Therapy) to targeted ischemic regions perfused by the patient’s left anterior descending coronary artery immediately following revascularization by means of percutaneous coronary intervention (PCI) with stenting that has been completed within 6 hours after the onset of anterior acute myocardial infarction (AMI) symptoms caused by a left anterior descending artery infarct lesion.

Source documents

Other decisions for Zoll Circulation, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

7 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.